Fundraising Fox
Arrakis Therapeutics
Cambridge, US · Founded 2015 · Delaware corporation · 53 employees on LinkedIn · 10 known investors
Find your way into Arrakis Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Issi Rozen to introduce you to David Neafus
You →Issi · together at Verve Therapeutics →David
Sign up to find every way you can get introduced to Arrakis Therapeutics
- Your email: who you already know at Arrakis Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Arrakis Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease. Its pipeline includes a candidate for Type 1 Myotonic Dystrophy (DM1), a form of muscular dystrophy.
Founders & leadership
Arrakis Therapeutics was founded in 2015 by Michael Gilman and Mark DeLong.
Board
Investors · 10
How we know: Canaan Partners's portfolio page · the company's own site · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: Advent Life Sciences's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · Not right? Tell us
How we know: Nextech Invest's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: funding news · the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$28.2M disclosed across 2 rounds · 2017–2019
▶$15MraisedApr 2019 · 15 investors · BiotechnologyRule 506(b)
- Nikola TrbovicDirector
- Raj ParekhDirector
- Michael GilmanExecutive Officer, Director
- Jakob LovenDirector
- Richard GasterDirector
- Colleen CuffaroDirector
- Offering amount
- $75M
- Amount sold
- $15M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$13.2MraisedMar 2017 · 8 investors · BiotechnologyRule 506(b)
- Colleen CuffaroDirector
- Michael GilmanExecutive Officer, Director
- Carolyn GreenDirector
- Alan E. WaltsDirector
- David NeafusExecutive Officer
- Raj ParekhDirector
- Russell C. PetterExecutive Officer
- Offering amount
- $41.2M
- Amount sold
- $13.2M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Arrakis Therapeutics.
In the news
Frequently asked questions
- What does Arrakis Therapeutics do?
- Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease. Its pipeline includes a candidate for Type 1 Myotonic Dystrophy (DM1), a form of muscular dystrophy.
- Who founded Arrakis Therapeutics?
- Arrakis Therapeutics was founded by Michael Gilman, Mark DeLong in 2015.
- Who are Arrakis Therapeutics's investors?
- Arrakis Therapeutics's investors include Canaan Partners, Pfizer Ventures, Advent Life Sciences, HBM Healthcare Investments, HBM Partners, Nextech Invest, OUP (Osage University Partners), Pfizer Venture Investments and 2 more.
- How much funding has Arrakis Therapeutics raised?
- Arrakis Therapeutics has disclosed $28.2M raised across 2 rounds.
- Where is Arrakis Therapeutics headquartered?
- Arrakis Therapeutics is headquartered in Cambridge, US.